Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 3
1964 1
1966 2
1968 1
1969 1
1970 2
1971 1
1975 1
1976 1
1977 2
1979 4
1980 6
1981 7
1982 4
1983 7
1984 4
1985 4
1986 6
1987 9
1988 7
1989 11
1990 6
1991 8
1992 5
1993 6
1994 4
1995 8
1996 6
1997 7
1998 14
1999 17
2000 13
2001 15
2002 16
2003 20
2004 14
2005 14
2006 21
2007 26
2008 19
2009 16
2010 18
2011 20
2012 25
2013 26
2014 27
2015 37
2016 36
2017 32
2018 33
2019 29
2020 30
2021 46
2022 31
2023 35
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

700 results

Results by year

Filters applied: . Clear all
Page 1
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study.
Siderowf A, Concha-Marambio L, Lafontant DE, Farris CM, Ma Y, Urenia PA, Nguyen H, Alcalay RN, Chahine LM, Foroud T, Galasko D, Kieburtz K, Merchant K, Mollenhauer B, Poston KL, Seibyl J, Simuni T, Tanner CM, Weintraub D, Videnovic A, Choi SH, Kurth R, Caspell-Garcia C, Coffey CS, Frasier M, Oliveira LMA, Hutten SJ, Sherer T, Marek K, Soto C; Parkinson's Progression Markers Initiative. Siderowf A, et al. Among authors: coffey cs. Lancet Neurol. 2023 May;22(5):407-417. doi: 10.1016/S1474-4422(23)00109-6. Lancet Neurol. 2023. PMID: 37059509 Free PMC article.
Adult Moyamoya Disease and Syndrome: Current Perspectives and Future Directions: A Scientific Statement From the American Heart Association/American Stroke Association.
Gonzalez NR, Amin-Hanjani S, Bang OY, Coffey C, Du R, Fierstra J, Fraser JF, Kuroda S, Tietjen GE, Yaghi S; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Gonzalez NR, et al. Among authors: coffey c. Stroke. 2023 Oct;54(10):e465-e479. doi: 10.1161/STR.0000000000000443. Epub 2023 Aug 23. Stroke. 2023. PMID: 37609846 Free article. Review.
Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke.
Lyden P, Pryor KE, Coffey CS, Cudkowicz M, Conwit R, Jadhav A, Sawyer RN Jr, Claassen J, Adeoye O, Song S, Hannon P, Rost NS, Hinduja A, Torbey M, Lee JM, Benesch C, Rippee M, Rymer M, Froehler MT, Clarke Haley E, Johnson M, Yankey J, Magee K, Qidwai J, Levy H, Mark Haacke E, Fawaz M, Davis TP, Toga AW, Griffin JH, Zlokovic BV; NeuroNEXT Clinical Trials Network NN104 Investigators. Lyden P, et al. Among authors: coffey cs. Ann Neurol. 2019 Jan;85(1):125-136. doi: 10.1002/ana.25383. Epub 2019 Jan 7. Ann Neurol. 2019. PMID: 30450637 Free PMC article. Clinical Trial.
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research.
Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, Chowdhury S, Coffey C, Concha-Marambio L, Dam T, DiBiaso P, Foroud T, Frasier M, Gochanour C, Jennings D, Kieburtz K, Kopil CM, Merchant K, Mollenhauer B, Montine T, Nudelman K, Pagano G, Seibyl J, Sherer T, Singleton A, Stephenson D, Stern M, Soto C, Tanner CM, Tolosa E, Weintraub D, Xiao Y, Siderowf A, Dunn B, Marek K. Simuni T, et al. Among authors: coffey c. Lancet Neurol. 2024 Feb;23(2):178-190. doi: 10.1016/S1474-4422(23)00405-2. Lancet Neurol. 2024. PMID: 38267190 Review.
Natural history of infantile-onset spinal muscular atrophy.
Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Parsons J, Connolly AM, Chiriboga CA, McDonald C, Burnette WB, Werner K, Thangarajh M, Shieh PB, Finanger E, Cudkowicz ME, McGovern MM, McNeil DE, Finkel R, Iannaccone ST, Kaye E, Kingsley A, Renusch SR, McGovern VL, Wang X, Zaworski PG, Prior TW, Burghes AHM, Bartlett A, Kissel JT; NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators. Kolb SJ, et al. Among authors: coffey cs. Ann Neurol. 2017 Dec;82(6):883-891. doi: 10.1002/ana.25101. Epub 2017 Dec 8. Ann Neurol. 2017. PMID: 29149772 Free PMC article.
Predicting chronic postsurgical pain: current evidence and a novel program to develop predictive biomarker signatures.
Sluka KA, Wager TD, Sutherland SP, Labosky PA, Balach T, Bayman EO, Berardi G, Brummett CM, Burns J, Buvanendran A, Caffo B, Calhoun VD, Clauw D, Chang A, Coffey CS, Dailey DL, Ecklund D, Fiehn O, Fisch KM, Frey Law LA, Harris RE, Harte SE, Howard TD, Jacobs J, Jacobs JM, Jepsen K, Johnston N, Langefeld CD, Laurent LC, Lenzi R, Lindquist MA, Lokshin A, Kahn A, McCarthy RJ, Olivier M, Porter L, Qian WJ, Sankar CA, Satterlee J, Swensen AC, Vance CGT, Waljee J, Wandner LD, Williams DA, Wixson RL, Zhou XJ; A2CPS Consortium. Sluka KA, et al. Among authors: coffey cs. Pain. 2023 Sep 1;164(9):1912-1926. doi: 10.1097/j.pain.0000000000002938. Epub 2023 Jun 15. Pain. 2023. PMID: 37326643 Free PMC article. Review.
Stingray Envenomation.
O'Connell C, Myatt T, Clark RF, Coffey C, Nguyen BJ. O'Connell C, et al. Among authors: coffey c. J Emerg Med. 2019 Feb;56(2):230-231. doi: 10.1016/j.jemermed.2018.11.005. J Emerg Med. 2019. PMID: 30738566 No abstract available.
Reply.
Clark RF, Coffey C, Myatt T, Nguyen BJ, O'Connell C. Clark RF, et al. Among authors: coffey c. J Emerg Med. 2019 Feb;56(2):231-232. doi: 10.1016/j.jemermed.2018.09.049. Epub 2018 Nov 23. J Emerg Med. 2019. PMID: 30473403 No abstract available.
Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study.
Nowak RJ, Coffey CS, Goldstein JM, Dimachkie MM, Benatar M, Kissel JT, Wolfe GI, Burns TM, Freimer ML, Nations S, Granit V, Smith AG, Richman DP, Ciafaloni E, Al-Lozi MT, Sams LA, Quan D, Ubogu E, Pearson B, Sharma A, Yankey JW, Uribe L, Shy M, Amato AA, Conwit R, O'Connor KC, Hafler DA, Cudkowicz ME, Barohn RJ; NeuroNEXT NN103 BeatMG Study Team. Nowak RJ, et al. Among authors: coffey cs. Neurology. 2022 Jan 25;98(4):e376-e389. doi: 10.1212/WNL.0000000000013121. Neurology. 2022. PMID: 34857535 Free PMC article.
700 results